[{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"658df07a-1501-4c8c-8a3c-b8a40f1a83dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439149","created_at":"2021-01-18T21:22:06.430Z","updated_at":"2024-07-02T16:35:04.598Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)","source_id_and_acronym":"NCT04439149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-09"},{"id":"6428c24f-062b-49d2-a05b-9215f1b97e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04997993","created_at":"2021-08-10T14:52:49.902Z","updated_at":"2024-07-02T16:35:24.882Z","phase":"Phase 1","brief_title":"Leflunomide in Patients With PTEN-[] Advanced Solid Malignancies","source_id_and_acronym":"NCT04997993","lead_sponsor":"Deborah Doroshow","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-29"},{"id":"7b687780-b61c-439e-9b4e-196b803f25c3","acronym":"PAveMenT","url":"https://clinicaltrials.gov/study/NCT04360941","created_at":"2023-12-22T20:17:07.096Z","updated_at":"2024-07-02T16:35:25.341Z","phase":"Phase 1","brief_title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","source_id_and_acronym":"NCT04360941 - PAveMenT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • PIK3CA • TMB • PTEN • RB1","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation","tags":["PD-L1 • PIK3CA • TMB • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-22"},{"id":"3934af03-057a-40fc-b82b-923f171f3da0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00770185","created_at":"2021-01-18T02:54:34.894Z","updated_at":"2025-02-25T14:55:16.957Z","phase":"Phase 2","brief_title":"Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer","source_id_and_acronym":"NCT00770185","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Taltorvic (ridaforolimus)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 11/13/2008","start_date":" 11/13/2008","primary_txt":" Primary completion: 03/19/2012","primary_completion_date":" 03/19/2012","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"789a1736-ad24-4164-869f-53be93217e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04873206","created_at":"2021-05-05T11:52:35.340Z","updated_at":"2024-07-02T16:36:07.266Z","phase":"","brief_title":"Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies","source_id_and_acronym":"NCT04873206","lead_sponsor":"Sohag University","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2022-07-15"},{"id":"e1eb53c8-559c-4659-bbff-a5b5bcd0ecee","acronym":"Neo ALTTO","url":"https://clinicaltrials.gov/study/NCT00553358","created_at":"2021-01-17T17:13:14.615Z","updated_at":"2024-07-02T16:36:24.205Z","phase":"Phase 3","brief_title":"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","source_id_and_acronym":"NCT00553358 - Neo ALTTO","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA • PTEN • PI3K","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 expression • PTEN expression","tags":["HER-2 • PIK3CA • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 expression • PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 455","initiation":"Initiation: 01/05/2008","start_date":" 01/05/2008","primary_txt":" Primary completion: 05/27/2010","primary_completion_date":" 05/27/2010","study_txt":" Completion: 12/23/2019","study_completion_date":" 12/23/2019","last_update_posted":"2021-09-21"},{"id":"f7ef3a32-c39e-4a8b-ba39-902767a7f32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195376","created_at":"2021-01-18T04:47:04.621Z","updated_at":"2024-07-02T16:36:37.555Z","phase":"Phase 1","brief_title":"A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01195376","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2020-12-09"},{"id":"55442488-1d80-4dbc-ae5e-2273f0f75787","acronym":"","url":"https://clinicaltrials.gov/study/NCT01802320","created_at":"2021-01-18T07:58:45.783Z","updated_at":"2024-07-02T16:36:55.387Z","phase":"Phase 2","brief_title":"Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01802320","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression","tags":["KRAS • BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 08/05/2015","study_completion_date":" 08/05/2015","last_update_posted":"2019-09-20"},{"id":"d05357da-75ac-49bf-96c3-852077c019bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00820222","created_at":"2021-01-18T03:07:04.646Z","updated_at":"2024-07-02T16:37:01.025Z","phase":"Phase 3","brief_title":"Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00820222","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PTEN • IGF1 • NR3C1","pipe":" | ","alterations":" HER-2 positive • PTEN expression","tags":["HER-2 • PTEN • IGF1 • NR3C1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 540","initiation":"Initiation: 04/14/2009","start_date":" 04/14/2009","primary_txt":" Primary completion: 06/11/2012","primary_completion_date":" 06/11/2012","study_txt":" Completion: 03/22/2018","study_completion_date":" 03/22/2018","last_update_posted":"2019-04-02"},{"id":"8dd13a6c-3880-4d0f-a8f1-b3fa4ec07910","acronym":"","url":"https://clinicaltrials.gov/study/NCT00831324","created_at":"2021-01-18T03:09:47.732Z","updated_at":"2024-07-02T16:37:17.154Z","phase":"Phase 2","brief_title":"Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT00831324","lead_sponsor":"University of California, San Francisco","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-10-12"}]